Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eteplirsen extension study in Duchenne muscular dystrophy
NCT03985878Phase 2Terminated
- Sponsor
- Sarepta Therapeutics
- Start
- Jun 2019
- Primary completion
- Aug 2022
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of eteplirsen in Duchenne muscular dystrophy (DMD), sponsored by Sarepta Therapeutics. Primary endpoints: Number of Participants Experiencing Adverse Events up to 162 weeks, Number of Participants Experiencing Death Due to Adverse Events up to 162 weeks and 1 more. Started Jun 2019; status: terminated.
02
Drugs
eteplirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03985878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03985878.